Ossium Health Stock

www.ossiumhealth.com/Healthcare / BioTech & PharmaFounded: 2016Funding to Date: $124.87MM

Ossium, founded in 2016, is a healthcare company that is striving to build the world's first bone marrow bank to treat blood cancers, improve organ transplantation, and repair damage from radiation. The cells of the immune system are the human body’s natural defenders against disease. At Ossium, they are seeking to develop methods of recovering, preserving, and deploying these critical cells to keep disease at bay. Ossium is headquartered in San Francisco, California.

Register for Details

For more details on financing and valuation for Ossium Health, register or login.

Please provide a valid email address.

By registering, you agree to Forge’s Terms of Use. Already registered? Log in


Enterprise Value (based on primary financings)

Powered by Forge Data
Enterprise Value

View Enterprise Value for Ossium Health.

Register Today


Management Team

Kevin Caldwell ESQ
Co-Founder, Chief Executive Officer & President
Erik Woods Ph.D
Co-Founder, Chief Scientific Officer, Executive Vice President of Clinical Laboratory Improvement Amendments & Laboratory Director
Sagar Munjal MD
Chief Medical Officer & Senior Vice President
Margie Mathewson Ph.D
Senior Vice President of Business Operations
Brian Johnstone Ph.D
Vice President of Research

Board Members

Bill Trenchard
First Round Capital
Edgar Engleman MD
Vivo Capital

Other companies like Ossium Health in the BioTech & Pharma sector

Last Round Est. Valuation
Last Round Est. Valuation
Last Round Est. Valuation
Last Round Est. Valuation
Last Round Est. Valuation
Last Round Est. Valuation
Last Round Est. Valuation

News Highlights

Bioengineering company Ossium Health raises $52m in Series C
Bioengineering company Ossium Health has secured $52m in Series C funding for expanding its bone marrow stem cell bank. The funding will also be utilised by the company to advance its cell therapy clinical trials intended for the treatment of blood and immune diseases.
Updated on: Oct 3, 2023


Public news articles listed on this page have been curated by Forge based on several factors including, but not limited to, product updates, changes in organization structure, funding rounds, third-party valuations, and key personnel changes. Changes to this list of articles can be made at any time without notice and should not be relied upon for investment purposes. Forge does not verify the accuracy of the information contained in public news articles.